DyAnsys in the News

FDA Clears DyAnsys Neurostiniulation Device Priniary Relief to Treat Post-Cardiac Surgery Pain
FDA Clears DyAnsys Neurostiniulation Device Priniary Relief to Treat Post-Cardiac Surgery Pain

PALO ALTO, Calif., Sept. 22, 2022 /PR Newswire/ -- DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been approved to treat pain following a cardiac surgery.

The percutaneous electrical nerve stimulator (PENS) system can be used for...

Read More
FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat C-SectionPain
FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat C-SectionPain

PALO ALTO, Calif. , July 28, 2022 /PRNewswire/ -- DyAnsys, Inc., has announced that PrimaryRelief, a percutaneous electrical neurostimulation device, has been clearedto treat painfollowing a Caesarean-section (C-section).

The percutaneous electrical nerve stimulator (PENS) system can be...

Read More
FDA Clears DyAnsys Neurostimulation Device First Relief to treat Diabetic Neuropathic Pain
FDA Clears DyAnsys Neurostimulation Device First Relief to treat Diabetic Neuropathic Pain

PALO ALTO, Calif., July 14, 2022 /PRNewswire/ -- First Relief, a PENS (percutaneous electrical neurostimulation) device, has been cleared by the US Food and Drug Administration for multiple treatments up to 56 days for symptomatic relief of chronic, intractable pain from diabetic peripheral...

Read More
Une société genevoise annonce avoir reçu l'autorisation de la Food and Drug Administration américaine pour un dispositif médical portable destiné à traiter la toxicomanie

GENÈVE, 12 juin 2018 /PRNewswire/ -- DyAnsys Europe SARL a annoncé que sa société mère, DyAnsys Inc., a obtenu l'autorisation de la Food and Drug Administration américaine pour un dispositif de neurostimulation auriculaire destiné à traiter les symptômes du sevrage aux opioïdes sans narcotiques...

Read More
Drug Relief
Das Genfer Unternehmen gibt die Genehmigung der U. S. Food and Drug Administration für ein tragbares medizinisches System zur Behandlung von Drogenabhängigkeit bekannt

GENF, 12. Juni 2018 /PRNewswire/ -- DyAnsys Europe SARL hat bekannt gegeben, dass seine Muttergesellschaft, DyAnsys Inc., die Zulassung der U. S. Food and Drug Administration für ein aurikuläres Neurostimulationsgerät zur Behandlung der Symptome von Opioidentzug ohne Betäubungsmittel erhalten...

Read More

RSS

Email Us

Call Us